A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 10,717 shares of GILD stock, worth $978,997. This represents 0.05% of its overall portfolio holdings.

Number of Shares
10,717
Previous 2,152 398.0%
Holding current value
$978,997
Previous $147,000 510.88%
% of portfolio
0.05%
Previous 0.01%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$66.59 - $83.99 $570,343 - $719,374
8,565 Added 398.0%
10,717 $898,000
Q2 2024

Jul 15, 2024

SELL
$63.15 - $72.88 $6.2 Million - $7.16 Million
-98,220 Reduced 97.86%
2,152 $147,000
Q4 2023

Jan 31, 2024

BUY
$73.27 - $83.09 $90,488 - $102,616
1,235 Added 1.25%
100,372 $8.13 Million
Q3 2023

Oct 20, 2023

SELL
$73.94 - $80.67 $340,124 - $371,082
-4,600 Reduced 4.43%
99,137 $7.43 Million
Q2 2023

Jul 06, 2023

SELL
$76.01 - $86.7 $798,105 - $910,350
-10,500 Reduced 9.19%
103,737 $8 Million
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $1.25 Million - $1.43 Million
-21,000 Reduced 15.53%
114,237 $7.05 Million
Q2 2022

Aug 16, 2022

SELL
$57.72 - $65.01 $161,616 - $182,028
-2,800 Reduced 2.03%
135,237 $8.36 Million
Q4 2021

Feb 14, 2022

BUY
$64.88 - $73.64 $2.36 Million - $2.67 Million
36,300 Added 35.68%
138,037 $10 Million
Q3 2021

Oct 28, 2021

SELL
$67.69 - $73.03 $155,687 - $167,969
-2,300 Reduced 2.21%
101,737 $7.1 Million
Q2 2021

Jul 13, 2021

BUY
$63.47 - $69.35 $425,249 - $464,644
6,700 Added 6.88%
104,037 $7.16 Million
Q1 2021

May 07, 2021

BUY
$60.0 - $68.46 $732,000 - $835,211
12,200 Added 14.33%
97,337 $6.29 Million
Q4 2020

Mar 02, 2021

BUY
$56.65 - $64.55 $317,240 - $361,480
5,600 Added 7.04%
85,137 $4.96 Million
Q3 2020

Nov 09, 2020

SELL
$62.1 - $78.08 $62,100 - $78,080
-1,000 Reduced 1.24%
79,537 $5.03 Million
Q1 2020

Apr 22, 2020

BUY
$62.63 - $80.22 $256,783 - $328,902
4,100 Added 5.36%
80,537 $6.02 Million
Q4 2019

Jan 28, 2020

SELL
$61.62 - $67.78 $351,234 - $386,346
-5,700 Reduced 6.94%
76,437 $4.97 Million
Q2 2019

Jul 19, 2019

BUY
$61.87 - $69.38 $160,862 - $180,388
2,600 Added 3.27%
82,137 $5.55 Million
Q1 2019

May 09, 2019

BUY
$62.53 - $70.05 $81,289 - $91,065
1,300 Added 1.66%
79,537 $5.17 Million
Q3 2018

Oct 26, 2018

SELL
$71.28 - $78.92 $1.8 Million - $2 Million
-25,300 Reduced 24.44%
78,237 $6.04 Million
Q2 2018

Jul 10, 2018

BUY
$64.88 - $75.68 $220,591 - $257,312
3,400 Added 3.4%
103,537 $7.34 Million
Q4 2017

Jan 18, 2018

SELL
$71.15 - $83.52 $747,075 - $876,960
-10,500 Reduced 9.49%
100,137 $7.17 Million
Q3 2017

Oct 12, 2017

BUY
$72.11 - $85.47 $7.98 Million - $9.46 Million
110,637
110,637 $8.96 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Livforsakringsbolaget Skandia, Omsesidigt Portfolio

Follow Livforsakringsbolaget Skandia, Omsesidigt and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Livforsakringsbolaget Skandia, Omsesidigt, based on Form 13F filings with the SEC.

News

Stay updated on Livforsakringsbolaget Skandia, Omsesidigt with notifications on news.